Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785873 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03785873 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT03785873, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for patients with advanced or metastatic biliary tract cancer after progression on first-line systemic therapy.
Interventions
- DRUG Leucovorin
- DRUG Nivolumab
- DRUG 5-Fluorouracil
- DRUG Nanoliposomal-Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785873
The ClinicalTrials.gov registry entry for NCT03785873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT03785873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785873 about?
NCT03785873 is a clinical study titled "Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer". The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for patients with advanced or metastatic biliary tract cancer after progressio...
What is the current status of trial NCT03785873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-05-22. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT03785873?
The interventions under investigation include: Leucovorin (DRUG), Nivolumab (DRUG), 5-Fluorouracil (DRUG), Nanoliposomal-Irinotecan (DRUG).
Who is sponsoring clinical trial NCT03785873?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.